Avenue Therapeutics, Inc.
ATXI
$0.28
-$0.03-8.35%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -65.60% | -32.30% | -34.02% | -37.41% | 13.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.52% | -40.16% | -77.06% | -60.80% | -48.61% |
| Operating Income | 62.52% | 40.16% | 77.06% | 110.52% | 48.61% |
| Income Before Tax | 62.59% | 53.43% | 77.58% | 112.18% | 57.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.59% | 53.43% | 77.58% | 112.18% | 57.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 13.33% | -18.18% | -33.33% | -33.33% |
| Net Income | 62.47% | 54.08% | 77.80% | 112.44% | 57.33% |
| EBIT | 62.52% | 40.16% | 77.06% | 110.52% | 48.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 66.15% | 72.66% | 88.84% | -92.76% | 95.95% |
| Normalized Basic EPS | 66.08% | 65.03% | 88.91% | 104.43% | 91.93% |
| EPS Diluted | 66.15% | 72.66% | 88.84% | -92.76% | 95.95% |
| Normalized Diluted EPS | 66.08% | 65.03% | 88.91% | 104.43% | 91.93% |
| Average Basic Shares Outstanding | 10.87% | 68.00% | 98.95% | 184.81% | 428.61% |
| Average Diluted Shares Outstanding | 10.87% | 68.00% | 98.95% | 184.81% | 428.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |